dermatology
Why target IL-31 for itch?
Open access · cc by · source: Europe PMC
This review argues IL-31/IL-31R drive pruritus across skin diseases and highlights nemolizumab as the late-stage antibody against the IL-31 receptor.
Key findings
Elevated IL-31 or receptor levels appear in multiple pruritic diseases; serum IL-31 in atopic dermatitis tracks severity/itch. Current antipruritics are often inadequate. Among pipeline agents, only nemolizumab (anti-IL-31R mAb) had successfully completed late-stage clinical studies at the time of writing.
Methodology
Synthesized evidence that IL-31 (identified 2004) and its receptor contribute to itch and barrier/inflammatory signs, summarizing elevated IL-31 signaling in atopic dermatitis, prurigo nodularis, and psoriasis and surveying emerging anti-IL-31 strategies.
Limitations
Narrative review—not a new RCT meta-analysis; drug landscape may have changed after 2021 publication.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Related papers in this topic
Same topic cluster — not a recommendation engine.